Reading: Sellas Life Sciences says GPS cut death risk in AML Phase 3 trial

Sellas Life Sciences says GPS cut death risk in AML Phase 3 trial

Published
3 min read
Advertisement

Sellas Life Sciences said on Tuesday that its experimental cancer vaccine Galinpepimut-S met the main goal of a pivotal Phase 3 trial in acute myeloid leukemia, cutting the risk of death by 41% versus the best available treatment. The company said it is now preparing for talks with the U.S. Food and Drug Administration before any filing plan can move ahead.

The study followed 126 patients with AML who were in a second or later remission and could not undergo a stem cell transplant. In that group, median overall survival was 24 months with Galinpepimut-S, compared with 14.7 months for the best available treatment, and Sellas said the result was statistically significant with a hazard ratio of 0.59 and a p-value of 0.035.

For Sellas, the number matters because the trial had already reached its prespecified 80th event last month, opening the door to the final analysis that is now being reported. Angelos Stergiou said the company wants to discuss the results and the regulatory path with the FDA as quickly as possible so the therapy can reach patients faster.

- Advertisement -

The detail that will shape the next step is not the survival gain alone, but what Sellas can persuade regulators to accept as the basis for an accelerated filing strategy. The company said it is still carrying out further analyses, and the results will be presented at an upcoming major medical conference and submitted for publication in a peer-reviewed medical journal before the planned Biologics License Application submission in the first half of 2027.

Sellas also said the treatment was generally well tolerated, with no new safety concerns and mostly mild or moderate side effects that were mainly injection-site reactions. Galinpepimut-S, also called GPS, is licensed from Memorial Sloan Kettering Cancer Center and is designed to help the immune system identify and attack leukemia cells by targeting WT1, a protein found in multiple cancers. SLS shares were up 7.1% pre-market before trading was halted, and the stock has gained more than 112% so far in 2026.

The question now is whether the FDA accepts the package Sellas is building from the trial results, the remaining analyses and the upcoming presentation and publication. That answer will determine whether the company can turn a positive survival readout into a filing path, or whether it has to do more work before the vaccine can move closer to patients.

Advertisement
Share This Article